PercAssist Announces First Patient Enrolled in AVANXA Clinical Feasibility Study using the eVAD™ System for Biventricular Mechanical Circulatory Support
PercAssist, Inc., a medical device company developing innovative technology for extravascular Biventricular Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced the first patient enrollment for the AVANXA Feasibility Study was successfully conducted in São Paulo, Brazil.
“I am thrilled to share the successful clinical use of the PercAssist eVAD System in a patient with SCAI Stage D CS,” said Gerardo Noriega, president and CEO of PercAssist. “The patient had limited CS treatment options, and the PercAssist eVAD System provided the needed support to aid in hemodynamic recovery over a two and a half-day period. The extravascular, intrapericardial balloon implant requires no large vessel access, and the system avoids many of the current standard of care complications, such as major bleeding, hemolysis and limb ischemia. PercAssist is looking forward to continued enrollment in our clinical program with Alexandre Abizaid, M.D., Ph.D., Carlos Campos, M.D., Ph.D., and Roger Renault Godinho, M.D., Ph.D., in São Paulo, Brazil.”
